Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113


Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines.

Hannani D, Locher C, Yamazaki T, Colin-Minard V, Vetizou M, Aymeric L, Viaud S, Sanchez D, Smyth MJ, Bruhns P, Kroemer G, Zitvogel L.

Cell Death Differ. 2014 Jan;21(1):50-8. doi: 10.1038/cdd.2013.60. Epub 2013 Jun 7.


Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.

Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, Prada N, Adjemian S, Catani JP, Freudenberg M, Galanos C, André F, Kroemer G, Zitvogel L.

Cell Death Differ. 2014 Jan;21(1):69-78. doi: 10.1038/cdd.2013.72. Epub 2013 Jun 28.


Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia.

Wemeau M, Kepp O, Tesnière A, Panaretakis T, Flament C, De Botton S, Zitvogel L, Kroemer G, Chaput N.

Cell Death Dis. 2010 Dec 2;1:e104. doi: 10.1038/cddis.2010.82.


Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.

Chaput N, De Botton S, Obeid M, Apetoh L, Ghiringhelli F, Panaretakis T, Flament C, Zitvogel L, Kroemer G.

J Mol Med (Berl). 2007 Oct;85(10):1069-76. Epub 2007 May 22. Review.


Calreticulin exposure dictates the immunogenicity of cancer cell death.

Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G.

Nat Med. 2007 Jan;13(1):54-61. Epub 2006 Dec 24.


Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway.

Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G.

Clin Cancer Res. 2010 Jun 15;16(12):3100-4. doi: 10.1158/1078-0432.CCR-09-2891. Epub 2010 Apr 26.


Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.

Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, Lasarte JJ, Matsuzaki G, Ikuta K, Ryffel B, Benlagha K, Tesnière A, Ibrahim N, Déchanet-Merville J, Chaput N, Smyth MJ, Kroemer G, Zitvogel L.

J Exp Med. 2011 Mar 14;208(3):491-503. doi: 10.1084/jem.20100269. Epub 2011 Mar 7. Erratum in: J Exp Med. 2011 Apr 11:208(4):869.


Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.

West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH.

Breast Cancer Res. 2011;13(6):R126. doi: 10.1186/bcr3072. Epub 2011 Dec 8.


Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.

García-Martínez E, Gil GL, Benito AC, González-Billalabeitia E, Conesa MA, García García T, García-Garre E, Vicente V, Ayala de la Peña F.

Breast Cancer Res. 2014 Nov 29;16(6):488. doi: 10.1186/s13058-014-0488-5.


CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy.

Ma Y, Mattarollo SR, Adjemian S, Yang H, Aymeric L, Hannani D, Portela Catani JP, Duret H, Teng MW, Kepp O, Wang Y, Sistigu A, Schultze JL, Stoll G, Galluzzi L, Zitvogel L, Smyth MJ, Kroemer G.

Cancer Res. 2014 Jan 15;74(2):436-45. doi: 10.1158/0008-5472.CAN-13-1265. Epub 2013 Dec 3.


Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy.

Ma Y, Yamazaki T, Yang H, Kepp O, Galluzzi L, Zitvogel L, Smyth MJ, Kroemer G.

Oncoimmunology. 2013 Jun 1;2(6):e24786. Epub 2013 Apr 30.


Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens.

Wijayahadi N, Haron MR, Stanslas J, Yusuf Z.

J Chemother. 2007 Dec;19(6):716-23.


Ecto-calreticulin in immunogenic chemotherapy.

Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, van Endert P, Ghiringhelli F, Apetoh L, Chaput N, Flament C, Ullrich E, de Botton S, Zitvogel L, Kroemer G.

Immunol Rev. 2007 Dec;220:22-34. Review.


Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, Signore M, De Ninno A, Lucarini V, Peschiaroli F, Businaro L, Gerardino A, Manic G, Ulas T, Günther P, Schultze JL, Kepp O, Stoll G, Lefebvre C, Mulot C, Castoldi F, Rusakiewicz S, Ladoire S, Apetoh L, Bravo-San Pedro JM, Lucattelli M, Delarasse C, Boige V, Ducreux M, Delaloge S, Borg C, André F, Schiavoni G, Vitale I, Laurent-Puig P, Mattei F, Zitvogel L, Kroemer G.

Science. 2015 Nov 20;350(6263):972-8. doi: 10.1126/science.aad0779. Epub 2015 Oct 29.


Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.

Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L.

Cancer Res. 2008 Jun 1;68(11):4026-30. doi: 10.1158/0008-5472.CAN-08-0427. Review.


CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.

Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ, Stagg J.

Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11091-6. doi: 10.1073/pnas.1222251110. Epub 2013 Jun 17.


Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.

Bauer C, Sterzik A, Bauernfeind F, Duewell P, Conrad C, Kiefl R, Endres S, Eigler A, Schnurr M, Dauer M.

Cancer Immunol Immunother. 2014 Apr;63(4):321-33. doi: 10.1007/s00262-013-1510-y. Epub 2014 Jan 3.


The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death.

Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, Fimia GM, Kepp O, Piacentini M, Froehlich KU, van Endert P, Zitvogel L, Madeo F, Kroemer G.

Cell Death Differ. 2008 Sep;15(9):1499-509. doi: 10.1038/cdd.2008.67. Epub 2008 May 9.


Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.

Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR.

Int J Cancer. 2013 Aug 1;133(3):624-36. doi: 10.1002/ijc.28070. Epub 2013 Mar 16.

Supplemental Content

Support Center